CTLA4-Ig (Abatacept) for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At-Risk for T1D

(HIC# 1211011152)

TrialNet investigators want to test a drug called Abatacept to see if it delays or prevents diabetes in people who are at risk of developing the disease. In this study, we will compare people who get infusions of Abatacept with people who get infusions that look the same, but have no Abatacept, called placebo. Abatacept is given through an intravenous (IV) infusion for a total of 14 doses over 12 months. Each infusion lasts 30 minutes. Most visits last about 2 hours. Follow up visits occur at specified intervals.

You can screen for this study if:
You are at least 6 years old AND
The tests you took in the Pathway to Prevention/Natural History Study showed that you are at heightened risk for developing type 1 diabetes

For more information, contact Laurie Feldman (203) 737-2760 or laurie.feldman@yale.edu